Takeda Submits New Drug Application In The U.S. For Investigational Type 2 Diabetes Therapy, Fixed-Dose Combination Alogliptin/Metformin

Podiatry Arena Takeda Submits New Drug Application In The U.S. For Investigational Type 2 Diabetes Therapy, Fixed-Dose Combination Alogliptin/Metformin

Welcome to the Podiatry Arena forums, for communication between foot health professionals about podiatry and related topics.

You are currently viewing our podiatry forum as a guest which gives you limited access to view all podiatry discussions and access our other features. By joining our free global community of Podiatrists and other interested foot health care professionals you will have access to post podiatry topics (answer and ask questions), communicate privately with other members (PM), upload content, view attachments, receive a weekly email update of new discussions, earn CPD points and access many other special features. Registered users do not get displayed the advertisments in posted messages. Registration is fast, simple and absolutely free so please, join our global Podiatry community today!

If you have any problems with the registration process or your account login, please contact contact us.

Takeda Submits New Drug Application In The U.S. For Investigational Type 2 Diabetes Therapy, Fixed-Dose Combination Alogliptin/Metformin

Submit Thread >

< Submit Thread

Thread Tools

Display Modes

27th November 2011, 04:20 AM

RSSFeedBot RSSFeedBot is offline

I, Robot

About:

Join Date: Jul 2008

Posts: 10,110

Join Date: Jul 2008

Marketplace reputation 0% (0)

CPD Points: 1

Thanks: 0

Thanked 19 Times in 19 Posts

Takeda Submits New Drug Application In The U.S. For Investigational Type 2 Diabetes Therapy, Fixed-Dose Combination Alogliptin/Metformin

Podiatry Arena members do not see these ads

Takeda Pharmaceutical Company Limited (Takeda) announced that its wholly-owned subsidiary Takeda Global Research & Development Center, Inc., U.S., submitted a New Drug Application (NDA) to the United States (U.S.) Food and Drug Administration (FDA) for the fixed-dose combination therapy alogliptin/metformin, which combines alogliptin with metformin in a single tablet...

More...

Sponsored Links

« Previous Thread | Next Thread »

Thread Tools
Show Printable Version Email this Page
Display Modes
Linear Mode Switch to Hybrid Mode Switch to Threaded Mode

Posting Rules
You may not post new threads You may not post replies You may not post attachments You may not edit your posts	vB code is On Smilies are On [IMG] code is On HTML code is On

Forum Jump

Translate This Page

Similar Threads

Thread	Thread Starter	Forum	Replies	Last Post
U.S. Food And Drug Administration (FDA) Delays Review Of Takeda's Investigational Type 2 Diabetes Therapies, Alogliptin And Alogliptin/Pioglitazone	RSSFeedBot	Latest Diabetes Medicine Research & News	0	19th November 2011 05:10 AM
Merck Announces FDA Acceptance Of New Drug Application For An Investigational Extended-Release Formulation Of JANUMET(R) For Type 2 Diabetes	RSSFeedBot	Latest Diabetes Medicine Research & News	0	13th January 2011 06:10 AM
52-Week Phase 3 Study Found Investigational Drug Dapagliflozin Plus Metformin Similar To Glipizide Plus Metformin In Improving HbA1c	RSSFeedBot	Latest Diabetes Medicine Research & News	0	25th September 2010 05:10 AM
Fixed-Dose Sitagliptin/Metformin (Janumet) Combo Tops Pioglitazone (Actos) For Glycemic Control In Type 2 Diabetics	RSSFeedBot	Latest Diabetes Medicine Research & News	0	27th June 2010 01:30 PM
PrandiMet(R), First Repaglinide And Metformin HCl Fixed Dose Combination Therapy, Now Available In The United States	RSSFeedBot	Latest Diabetes Medicine Research & News	0	8th February 2009 05:10 AM

New To Site?	Need Help?
Register to Participate View Forum Leaders Contact Us	Frequently Asked Questions Did you forget your password? Mark Forums Read

Finding your way around:

Browse the forums.

Search the site.

Browse the tags.

Search the tags.

All times are GMT -7. The time now is 05:51 AM.

User Name		Remember Me?
Password